When it is understood that uplisting will be from strength and that catalysts are needed after the uplist, I am thinking about the ducks that will be lined up before and after the uplist.

In this regard, the ducks have to be staged.

And business is about control.

Possible ducks that are within AMBS control:
1. Submission of ODD applications (with predictable FDA approval timeline)
2. Start of Elto trial
3. Update of Data/Studies/Status (Lympro, MANF, Phenoguard)
4. Launch of Lympro CLIA
5. Distribution/Sale of Lympro
6. Spin-off / Restructure (e.g. breakup of Therapeutics Division to Ophthalmology Division, Diabetes Division + spin-off etc)

Possible ducks that are not within AMBS control:
1. Grants
2. Acquisition of Assets
3. Partnership
4. Buyout

If a partnership, buyout etc agreement/contract is signed or structured such that its completion or effective date is pending certain occurrence of events (e.g. data/studies results release or application outcome), then the timing of a partnership/buyout PR can be controlled by AMBS to a certain extent.

AMBS may have an ingenious game plan up its sleeve.